SCHEMBL162509

SCHEMBL162509

Oc1nc(C(F)(F)c2ncc(F)cn2)nc2c(Cl)cccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 3/20 0.38
PARP1 P09874 3/20 0.33
MAP4K4 O95819 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
JAK2 O60674 2/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
PRKD3 O94806 1/20 0.33
PAK4 O96013 1/20 0.33
ABL1 P00519 1/20 0.33
CSF1R P07333 1/20 0.33
RET P07949 1/20 0.33
IGF1R P08069 1/20 0.33
MET P08581 1/20 0.33
PDGFRB P09619 1/20 0.33
PIM1 P11309 1/20 0.33
FGFR1 P11362 1/20 0.33
PDGFRA P16234 1/20 0.33
PRKACA P17612 1/20 0.33
FLT1 P17948 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161725 0.78 ADORA2A (0.38) MEN1KMT2A
SCHEMBL158446 0.73 PDE7A (0.33) PDE7APARP1MAP4K4CLK4JAK2
SCHEMBL174983 0.73 AURKA (0.48) JAK2AURKAPAK4RETFGFR1
SCHEMBL163623 0.71 NR1H2 (0.35) PARP1MAP4K4CLK4AURKAPRKD3
SCHEMBL160936 0.71 ENPP3 (0.36)
SCHEMBL158172 0.69 ADORA2A (0.41) MEN1KMT2ATNKSTNKS2
SCHEMBL162284 0.69 KDM4E (0.36) PIM1NR4A2DHODH
SCHEMBL182945 0.69 GRM2 (0.39) PARP1MEN1KMT2ATNKSTNKS2
SCHEMBL15845928 0.68 NR4A2 (0.43) PDE7APARP1MAP4K4CLK4JAK2
SCHEMBL161396 0.68 PDE10A (0.36) PIM1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633207-B2 Quinazoline compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2014-01-21 US disclosed
EP-2611789-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 EP disclosed
WO-2012030948-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF JAK3, JAK2, TYK2 PDE7A 1632/4885PARP1 1231/4885MAP4K4 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.